Evaxion Biotech A/S (EVAX) announced the expansion of its vaccine pipeline with the addition of EVX-B4, a novel vaccine candidate targeting Group A Streptococcus or GAS.
This new program is powered by the company's proprietary AI-Immunology platform.
Group A Streptococcus is responsible for hundreds of millions of infections globally each year, ranging from common illnesses like strep throat and scarlet fever to severe and life-threatening conditions such as rheumatic heart disease and necrotizing fasciitis. There is currently no approved preventive vaccine for GAS.
According to Evaxion, initial computational analysis confirms that its AI-Immunology technology can rapidly identify and validate novel vaccine targets, accelerating the preclinical development of EVX-B4.
The company aims to build a comprehensive preclinical data package to support future partnerships and out-licensing opportunities.
CSO Birgitte Rønø noted that GAS was prioritized due to its global health impact and lack of preventive options.
EVX-B4 becomes the fifth infectious disease vaccine candidate in Evaxion's pipeline, which also includes three cancer vaccine programs, furthering its strategic goal of building a partner-ready vaccine portfolio.
The decision to advance EVX-B4 aligns with Evaxion's 2025 R&D milestones and reinforces the commercial and medical urgency in addressing invasive and non-invasive GAS infections worldwide.
Currently, EVAX is trading at $2.40, down by 1.96 percent on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.